Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Time to progression · women with hormone‐sensitive advanced breast cancer

Fulvestrant showed no clear difference in time to progression compared with other endocrine treatment (moderate certainty).

1 finding from 1 review

Fulvestrant for hormone‐sensitive metastatic breast cancer 2017 · Cochrane Headline outcomes only
HR 0.95 [0.89, 1.02]
9 studies · 4258 participants
Moderate